Crinetics Pharmaceuticals (CRNX) Cash from Investing Activities (2017 - 2026)

Crinetics Pharmaceuticals' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$252.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 193.57% year-over-year to -$252.4 million; the TTM figure through Mar 2026 stood at $7.5 million (up 101.14% YoY), while the FY2025 annual figure was $173.9 million, up 130.25% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$252.4 million, down from $57.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $164.8 million in Q3 2025, with the low at -$542.1 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is $309000.0 (2024), against an average of -$60.5 million.
• Peak annual rise in Cash from Investing Activities reached 699.93% in 2025, while the deepest fall reached 27919.09% in 2025.
• Crinetics Pharmaceuticals' Cash from Investing Activities stood at $36.9 million in 2022, then slumped by 336.91% to -$87.3 million in 2023, then tumbled by 520.89% to -$542.1 million in 2024, then jumped by 110.53% to $57.1 million in 2025, then slumped by 541.91% to -$252.4 million in 2026.
• Business Quant data shows CRNX's Cash from Investing Activities at -$252.4 million in Q1 2026, $57.1 million in Q4 2025, and $164.8 million in Q3 2025.